Millipore Sigma Vibrant Logo

233552 Cobra Venom Factor, Naja naja kaouthia

Cobra Venom Factor, Naja naja kaouthia, is a native cobra venom factor. Glycoprotein composed of three non-identical disulfide-bonded subunits of 68, 48, and 30 kDa.

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: Cobra Venom Anticomplementary Protein

View Products on Sigmaaldrich.com
233552
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
233552-1MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 1 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewNative cobra venom factor from Naja naja kaouthia. Glycoprotein composed of three non-identical disulfide-bonded subunits with M.W. of 68 kDa (α), 48 kDa (β), and 30 kDa (γ). Cobra venom factor (CVF) is a structural and functional analog of cobra, as well as mammalian C3. Thus, in the presence of Factor B, Factor D, and Mg2+, CVF can form a stable CVF,Bb complex that is a C3/C5 convertase enzyme; however, the CVF,Bb complex is not susceptible to regulation by Factors H and I. Four to six µg of purified CVF are equal to 1.0 unit of functional activity as measured by the method of Cochrane, et al.
      Catalogue Number233552
      Brand Family Calbiochem®
      SynonymsCobra Venom Anticomplementary Protein
      References
      ReferencesBogers, W.M., et al. 1993. Eur. J. Immunol. 23, 433.
      Fritzinger, D.C., et al. 1992. J. Immunol. 149, 3554.
      Muller, B. and Muller-Ruchholtz, W. 1987. Leuk. Res. 11, 461.
      Vogel, C.W. and Muller-Eberhard, H.J. 1984. J. Immunol. Methods 73, 203.
      Cochrane, C.G., et al. 1970. J. Immunol. 105, 55.
      Ballows, M. and Cochrane, C.G. 1969. J. Immunol. 103, 944.
      Product Information
      Activity≥250 units/ml
      DeclarationNot available for sale outside the United States.
      FormLiquid
      FormulationIn PBS, pH 7.2.
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      ContaminantsPhospholipase: none detected
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 20/21/22

      Harmful by inhalation, in contact with skin and if swallowed.
      S PhraseS: 36

      Wear suitable protective clothing.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Harmful
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      233552-1MG 04055977217896

      Documentation

      Cobra Venom Factor, Naja naja kaouthia Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Cobra Venom Factor, Naja naja kaouthia Certificados de análisis

      CargoNúmero de lote
      233552

      Referencias bibliográficas

      Visión general referencias
      Bogers, W.M., et al. 1993. Eur. J. Immunol. 23, 433.
      Fritzinger, D.C., et al. 1992. J. Immunol. 149, 3554.
      Muller, B. and Muller-Ruchholtz, W. 1987. Leuk. Res. 11, 461.
      Vogel, C.W. and Muller-Eberhard, H.J. 1984. J. Immunol. Methods 73, 203.
      Cochrane, C.G., et al. 1970. J. Immunol. 105, 55.
      Ballows, M. and Cochrane, C.G. 1969. J. Immunol. 103, 944.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision20-December-2010 JSW
      SynonymsCobra Venom Anticomplementary Protein
      DescriptionNative cobra venom factor from Naja naja kaouthia. Glycoprotein composed of three nonidentical disulfide-bound subunits with M.W. of 68,000 (α), 48,000 (β), and 30,000 (γ). Cobra Venom Factor (CVF) is a structural and functional analog of cobra, as well as mammalian C3. In the presence of Factor B, Factor D, and Mg2+, CVF can form a stable CVF, Bb complex which is a C3/C5 convertase enzyme; however, the CVF,Bb complex is not susceptible to regulation by Factors H and I. Four to six µg of purified CVF is equal to 1.0 unit of functional activity as measured by the method of Cochrane, et al.
      FormLiquid
      FormulationIn PBS, pH 7.2.
      Concentration Label Please refer to vial label for lot-specific concentration
      Purity≥95% by SDS-PAGE
      ContaminantsPhospholipase: none detected
      Activity≥250 units/ml
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Harmful
      ReferencesBogers, W.M., et al. 1993. Eur. J. Immunol. 23, 433.
      Fritzinger, D.C., et al. 1992. J. Immunol. 149, 3554.
      Muller, B. and Muller-Ruchholtz, W. 1987. Leuk. Res. 11, 461.
      Vogel, C.W. and Muller-Eberhard, H.J. 1984. J. Immunol. Methods 73, 203.
      Cochrane, C.G., et al. 1970. J. Immunol. 105, 55.
      Ballows, M. and Cochrane, C.G. 1969. J. Immunol. 103, 944.